On 15 September, the Guangdong Provincial Medical Products Administration (GDMPA) and the Health Commission of Guangdong Province jointly announced measures for the administration of catalogue of Hong Kong and Macao-registered drugs and medical devices for urgent clinical use in the Guangdong-Hong Kong-Macao Greater Bay Area’s nine Mainland cities.

Foreign and domestic medical device facilities – including any Mainland China or Hong Kong facilities – that do not properly renew their registrations with the FDA can be locked out of the U.S. market. Renewals for such facilities are due each year.

On 21 August, the State Council announced that it had approved in principle a plan to accelerate opening up and innovation across the entire biopharmaceutical industrial chain in the China (Jiangsu) Pilot Free Trade Zone.

The FDA has issued an import alert that it said aims to help stop imports of potentially dangerous GLP-1 (glucagon-like peptide-1) active pharmaceutical ingredients from unverified foreign sources.